<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209417</url>
  </required_header>
  <id_info>
    <org_study_id>DXV406</org_study_id>
    <nct_id>NCT00209417</nct_id>
  </id_info>
  <brief_title>Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography</brief_title>
  <official_title>GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ABX CRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Examination Management Services Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Averion International Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <brief_summary>
    <textblock>
      It is well known that X-ray contrast media can affect kidney function in some patients,
      especially when administered intra-arterially, and patients who already suffer from reduced
      kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use
      low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast
      media-induced nephropathy. However, little is known about the intravenous use of X-ray
      contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose
      of this study is to evaluate and compare the effects on kidney function of two contrast
      media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney
      damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is
      expected less influence on renal function following administration of iodixanol. A standard
      hydration procedure, based on available guidelines will be given to all patients to prevent
      negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured
      before and up to 7 days after contrast media administration to evaluate the effects on renal
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GEHC has decided not to provide this detail
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Supported by preliminary interim analysis. Not based on any safety signals in study or any
    quality issues that could affect efficacy of the product.
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.</measure>
    <time_frame>From baseline up to 3 days post contrast administration.</time_frame>
    <description>The primary endpoint was the incidence rate of CIN, defined as an intra-individual increase in serum creatinine (SCr) of greater than or equal to 44.2 µmol/L (greater than or equal to 0.5 mg/dL).
Subjects with a pre-contrast (baseline) serum creatinine value greater than or equal to 1.5 mg/dL for males and greater than or equal to 1.3 mg/dL for females or eGFR of less than or equal to 50 mL/min/1.73m squared, and a post-contrast serum creatinine value available on days 2 or 3, administered greater than or equal to100 mL or greater than or equal to 1.5 mL/kg bodyweight IMP, without presence of any major protocol violations, and without evidence of other causes inducing acute renal dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-enhanced Multi-detector-row Helical Computed Tomography (MDCT) Examination.</measure>
    <time_frame>Within 2, 3 and 7 days post contrast administration.</time_frame>
    <description>Overall Image Quality rated as &quot;Excellent, Good, Sufficient or Insufficient Poor&quot; by radiologists blinded to the contrast administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">656</enrollment>
  <condition>Renal Insufficiency</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Iodixanol 320-Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iodixanol 320 mg I/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iopamidol 300-Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iopamidol 300 mg I/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodixanol 320-Arm 1</intervention_name>
    <arm_group_label>Iodixanol 320-Arm 1</arm_group_label>
    <other_name>Visipaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iopamidol 300-Arm 2</intervention_name>
    <arm_group_label>Iopamidol 300-Arm 2</arm_group_label>
    <other_name>Isovue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a combination of diabetes mellitus (type I or II) and renal impairment
             who are referred for a contrast-enhanced CT examination.

        Exclusion Criteria:

          -  Concurrent administration of potentially nephroprotective or nephrotoxic drugs is not
             permitted.

          -  Patients undergoing dialysis or kidney transplantation will not be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith A Johnson, MS, MBA</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Amersham</city>
        <zip>HP7 9LL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>October 2, 2014</results_first_submitted>
  <results_first_submitted_qc>October 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2014</results_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iodixanol</keyword>
  <keyword>Iopamidol</keyword>
  <keyword>computed tomography</keyword>
  <keyword>Patients with pre-existing renal impairment and diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>656 subjects enrolled. 8 subjects did not continue on in the study. 7 of the 8 subjects discontinued the study prior to contrast media administration and 1 of the 8 subjects received a contrast media of unknown type and was excluded from the study.
Subtracting 8 subjects from the total 656, a total of 648 subjects actually completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Iodixanol 320-Arm 1</title>
          <description>Iodixanol 320 mg I/mL
Iodixanol 320-Arm 1</description>
        </group>
        <group group_id="P2">
          <title>Iopamidol 300-Arm 2</title>
          <description>Iopamidol 300 mg I/mL
Iopamidol 300-Arm 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="321"/>
                <participants group_id="P2" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="321"/>
                <participants group_id="P2" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iodixanol 320-Arm 1</title>
          <description>Iodixanol 320 mg I/mL
Iodixanol 320-Arm 1</description>
        </group>
        <group group_id="B2">
          <title>Iopamidol 300-Arm 2</title>
          <description>Iopamidol 300 mg I/mL
Iopamidol 300-Arm 2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="321"/>
            <count group_id="B2" value="327"/>
            <count group_id="B3" value="648"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="12.02"/>
                    <measurement group_id="B2" value="66.5" spread="12.01"/>
                    <measurement group_id="B3" value="66.4" spread="12.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.</title>
        <description>The primary endpoint was the incidence rate of CIN, defined as an intra-individual increase in serum creatinine (SCr) of greater than or equal to 44.2 µmol/L (greater than or equal to 0.5 mg/dL).
Subjects with a pre-contrast (baseline) serum creatinine value greater than or equal to 1.5 mg/dL for males and greater than or equal to 1.3 mg/dL for females or eGFR of less than or equal to 50 mL/min/1.73m squared, and a post-contrast serum creatinine value available on days 2 or 3, administered greater than or equal to100 mL or greater than or equal to 1.5 mL/kg bodyweight IMP, without presence of any major protocol violations, and without evidence of other causes inducing acute renal dysfunction.</description>
        <time_frame>From baseline up to 3 days post contrast administration.</time_frame>
        <population>To calculate the incidence rate of CIN, divide the number of subjects affected by the total number of subjects dosed in each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Iodixanol 320-Arm 1</title>
            <description>Iodixanol 320 mg I/mL
Iodixanol 320-Arm 1</description>
          </group>
          <group group_id="O2">
            <title>Iopamidol 300-Arm 2</title>
            <description>Iopamidol 300 mg I/mL
Iopamidol 300-Arm 2</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.</title>
          <description>The primary endpoint was the incidence rate of CIN, defined as an intra-individual increase in serum creatinine (SCr) of greater than or equal to 44.2 µmol/L (greater than or equal to 0.5 mg/dL).
Subjects with a pre-contrast (baseline) serum creatinine value greater than or equal to 1.5 mg/dL for males and greater than or equal to 1.3 mg/dL for females or eGFR of less than or equal to 50 mL/min/1.73m squared, and a post-contrast serum creatinine value available on days 2 or 3, administered greater than or equal to100 mL or greater than or equal to 1.5 mL/kg bodyweight IMP, without presence of any major protocol violations, and without evidence of other causes inducing acute renal dysfunction.</description>
          <population>To calculate the incidence rate of CIN, divide the number of subjects affected by the total number of subjects dosed in each treatment group.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.90" lower_limit="5.67" upper_limit="14.12"/>
                    <measurement group_id="O2" value="10.63" lower_limit="6.43" upper_limit="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-enhanced Multi-detector-row Helical Computed Tomography (MDCT) Examination.</title>
        <description>Overall Image Quality rated as &quot;Excellent, Good, Sufficient or Insufficient Poor&quot; by radiologists blinded to the contrast administration.</description>
        <time_frame>Within 2, 3 and 7 days post contrast administration.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iodixanol 320-Arm 1</title>
            <description>Iodixanol 320 mg I/mL
Iodixanol 320-Arm 1</description>
          </group>
          <group group_id="O2">
            <title>Iopamidol 300-Arm 2</title>
            <description>Iopamidol 300 mg I/mL
Iopamidol 300-Arm 2</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-enhanced Multi-detector-row Helical Computed Tomography (MDCT) Examination.</title>
          <description>Overall Image Quality rated as &quot;Excellent, Good, Sufficient or Insufficient Poor&quot; by radiologists blinded to the contrast administration.</description>
          <units>Number of images</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Images Analyzed</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Image Quality-Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Image Quality-Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Image Quality-Sufficient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Image Quality-Insufficient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Iodixanol 320-Arm 1</title>
          <description>Iodixanol 320 mg I/mL
Iodixanol 320-Arm 1</description>
        </group>
        <group group_id="E2">
          <title>Iopamidol 300-Arm 2</title>
          <description>Iopamidol 300 mg I/mL
Iopamidol 300-Arm 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Cardiac Failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <description>Outcome was death for Iopamidol.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Aortic Dissection</sub_title>
                <description>Outcome was death for Iopamidol.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Lactic Acid Increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure Acute</sub_title>
                <description>Outcome was death for both Iodixanol and Iopamidol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <description>Outcome was death for Iodixanol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <description>Outcome was death for Iodixanol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <description>Outcome was death for Iopamidol.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Gordon, PhD</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>011-47-2318-5822</phone>
      <email>Paul.Gordon@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

